Literature DB >> 8356390

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis.

U Sack1, R W Kinne, T Marx, P Heppt, S Bender, F Emmrich.   

Abstract

Interleukin-6 (IL-6) was detected at low levels in plasma [0.014 +/- 0.006 ng/ml (mean +/- SEM] and in high amounts in synovial fluid [SF; 2.6 +/- 2.2 ng/ml (mean +/- SEM)] of patients with rheumatoid arthritis. No correlation of IL-6 levels in plasma or SF with the ESR (n = 15) or with histological parameters of acute local synovitis (n = 10) was observed. In contrast, SF IL-6 was positively correlated with histological characteristics of chronic synovitis (n = 10; P < or = 0.01) and elevated plasma IgG concentrations (n = 15; P < or = 0.05). In vitro concentrations of IL-6 comparable to those detected in SF increased the production of both IgG and IgM by synovial membrane mononuclear cells. The present results contribute to the view that high local IL-6 concentrations in SF promote chronic synovitis in RA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356390     DOI: 10.1007/bf00307733

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

1.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Analysis of the histologic variation of synovitis in rheumatoid arthritis.

Authors:  M Rooney; D Condell; W Quinlan; L Daly; A Whelan; C Feighery; B Bresnihan
Journal:  Arthritis Rheum       Date:  1988-08

3.  IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

Authors:  N Bhardwaj; U Santhanam; L L Lau; S B Tatter; J Ghrayeb; M Rivelis; R M Steinman; P B Sehgal; L T May
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

4.  Interleukin 1 induces different cytokines in human fibroblasts.

Authors:  J Van Damme; M R Schaafsma; R Conings; J P Lenaerts; W Put; A Billiau; W E Fibbe
Journal:  Lymphokine Res       Date:  1989

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis.

Authors:  G Vreugdenhil; B Löwenberg; H G van Eijk; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

7.  Interleukin 6 is essential for antibody secretion by human in vivo antigen-induced lymphoblastoid B cells.

Authors:  J A Brieva; R A Martin; O Martinez-Maza; J Kagan; J Merrill; A Saxon; J Van Damme; R H Stevens
Journal:  Cell Immunol       Date:  1990-10-15       Impact factor: 4.868

Review 8.  Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth.

Authors:  J Bauer
Journal:  Klin Wochenschr       Date:  1989-07-17

9.  Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis.

Authors:  E Hermann; B Fleischer; W J Mayet; T Poralla; K H Meyer zum Büschenfelde
Journal:  Clin Exp Rheumatol       Date:  1989 Jul-Aug       Impact factor: 4.473

10.  Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macrophages.

Authors:  A E Koch; J C Burrows; A Skoutelis; R Marder; P H Domer; B Anderson; S J Leibovich
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

View more
  40 in total

1.  Tocilizumab.

Authors:  Clemens Scheinecker; Josef Smolen; Uma Yasothan; Jeffrey Stoll; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

2.  Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis.

Authors:  Nada Bensaoud; Samira Rostom; Rachid Bahiri; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2015-04-23       Impact factor: 2.980

Review 3.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane.

Authors:  Tomoko Matsumoto; Toshiyuki Tsurumoto; Hiroyuki Shindo
Journal:  Rheumatol Int       Date:  2006-10       Impact factor: 2.631

Review 5.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

Review 6.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Drug Des Devel Ther       Date:  2010-10-01       Impact factor: 4.162

7.  Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.

Authors:  Linda L Hushaw; Ray Sawaqed; Ghaleb Sweis; Jori Reigle; Anjali Gopal; Daniel Brandt; Nadia Sweis; James Curran; Timothy B Niewold; Nadera J Sweiss
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 8.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

9.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Authors:  Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.